{"schema_version":"secwatch.filing_event.v1","accession":"0001787306-22-000030","form_type":"8-K","ticker":"ARQT","cik":"0001787306","company_name":"Arcutis Biotherapeutics, Inc.","filed_at":"2022-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.317971+00:00","generated_at":"2026-06-25T23:55:41.874544+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Arcutis Q1 net loss $64.3M ($1.27/sh); cash $344.8M; roflumilast PDUFA July 29","bullets":["Net loss widened to $64.3M ($1.27 per share) from $36.0M ($0.76) in Q1 2021.","Cash & securities $344.8M at Mar 31, down from $388.6M at Dec 31 2021; ATM added $14.5M.","PDUFA action date July 29, 2022 for roflumilast cream in plaque psoriasis; commercial prep underway.","Completed enrollment of pivotal Phase 3 trials for roflumilast foam in seborrheic dermatitis and scalp/body psoriasis.","R&D spend $40.6M vs $21.6M; G&A $22.0M vs $14.5M, driven by clinical and launch preparations."],"urls":{"canonical":"https://secwatch.observer/filing/0001787306-22-000030","json":"https://secwatch.observer/filing/0001787306-22-000030.json","markdown":"https://secwatch.observer/filing/0001787306-22-000030.md","text":"https://secwatch.observer/filing/0001787306-22-000030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787306/000178730622000030/0001787306-22-000030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787306/000178730622000030/arqt-20220505.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T23:55:41.874544+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}